Prevalencia de síndrome metabólico en pacientes con enfermedad coronaria estable: objetivos terapéuticos y utilización de fármacos cardiovasculares

Lahoz, Carlos; Mostaza, José María; Mantilla, María Teresa; Taboada, Manuel; Tranche, Salvador; López-Rodríguez, Isidro; Monteiro, Beatriz P.; Sánchez-Zamorano, Miguel A.; Martín-Jadraque, Raquel

doi:10.1016/j.rce.2010.05.018

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 For Spanish patients with established cardiovascular disease, the prevalence of MS is 37%, 21,22 which is also lower than the rate measured in our study. This could be due to the fact that patients with PAD have a greater burden of risk factors than patients who have ischemic heart disease or cerebrovascular disease (as revealed in the REACH study 23 ).…”

Section: Discussioncontrasting

confidence: 66%

“…Similar results have been obtained in Spanish patients with MS and stable coronary artery disease. 22 The design of our study did not allow us to determine the cause of this poorer control; however, the use of suboptimal dosages of drugs and poor treatment adherence could explain this result. The Spanish REACH registry, 23 which enrolled 2515 patients with cardiovascular risk factors or symptomatic vascular disease, found that patients with PAD used fewer statins and less antiplatelet therapy than those patients with coronary artery disease.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Metabolic syndrome in patients with peripheral arterial disease

Estirado

Lahoz

Laguna

et al. 2014

Revista Clínica Española (English Edition)

Self Cite

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 66%

Section: Discussionmentioning

confidence: 91%

Metabolic syndrome in patients with peripheral arterial disease

Estirado

Lahoz

Laguna

et al. 2014

Revista Clínica Española (English Edition)

Self Cite

View full text Add to dashboard Cite

“…The prevalence of hypercholesterolemia in patients with chronic CHD was more uniform than that found in patients with ACS, according to the information collected, ranging from 64% to 74% [ 32 – 38 , 44 – 46 ]. More than 80% of patients were receiving LLT, statins accounting for 95% of them [ 37 ].…”

Section: Resultsmentioning

confidence: 99%

Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain

et al. 2015

View full text Add to dashboard Cite

IntroductionCardiovascular diseases (CVDs) represent a major Public Health burden. High serum cholesterol levels have been linked to major CV risk. The objectives of this study were to review the epidemiology of hypercholesterolemia in high risk CV patients from Spain, by assessing its prevalence, the proportion of diagnosed patients undergoing pharmacological treatment and the degree of attained lipid control.MethodsA systematic literature review was carried out using Medline and two Spanish databases. Manuscripts containing information on hypercholesterolemia in several high CV risk groups [diabetes mellitus (DM), Systematic COronary Risk Evaluation (SCORE) risk >5, or documented CVD], published between January 2010 and October 2014, were included.ResultsOf the 1947 published references initially retrieved, a full-text review was done on 264 manuscripts and 120 were finally included. Prevalence of hypercholesterolemia ranged from 50 to 84% in diabetics, 30–60% in patients with DM or elevated SCORE risk, 64–74% with coronary heart disease, 40–70% in stroke patients, and 60–80% in those with peripheral artery disease. Despite the finding that most of them were on pharmacological treatment, acceptable control of serum lipids was very variable, ranging from 15% to 65%. Among those with heterozygous familial hypercholesterolemia, 95–100% received treatment but less than 50% achieved their therapeutic goals.ConclusionsAn elevated prevalence of hypercholesterolemia can be found in targeted groups at high CV risk. Although most patients are receiving pharmacological treatment, rates of lipid control continue to be low, both in primary and secondary prevention.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-015-0252-y) contains supplementary material, which is available to authorized users.

show abstract

“…De hecho, en el presente estudio solo el 60,4% de los médicos tenían en consideración las concentraciones de cLDL, cHDL y triglicéridos para valorar a un paciente dislipémico. En el mismo sentido, es destacable que ante un paciente de alto riesgo la mayoría de los facultativos, tanto de la atención primaria 8 como de la especializada, no asocian fármacos para controlar el exceso de triglicéridos, cuando este persiste a pesar del tratamiento con estatinas 9 . Es, por tanto, necesaria una mayor atención al perfil lipídico global por parte de los facultativos para vencer el mencionado problema de gestión de los análisis de laboratorio, ya que aunque las políticas desarrolladas a nivel macrosocial por los poderes públicos en materia de prevención tienen un papel fundamental 10 , cuando se trata de estrategias terapéuticas, estas deberían ser consensuadas con los médicos asistenciales.…”

Section: Discussionunclassified